Marinus Pharmaceuticals | MRNS - Gross Profit On Sales


Marinus Pharmaceuticals reported $-12.13M in Gross Profit on Sales for its fiscal quarter ending in June of 2024.



Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 257.76M 778K Dec/2025
ALKERMES USD 338.34M 72.51M Dec/2025
Amgen USD 6.48B 307M Sep/2025
Biogen USD 1.65B 34.6M Dec/2025
Eisai JPY 168.85B 17.02B Dec/2025
Enanta Pharmaceuticals -22.29M 23.75M Dec/2024
Esperion Therapeutics USD 140.59M 94.57M Dec/2025
Gilead Sciences USD 6.31B 106M Dec/2025
Incyte USD 1.39B 118.68M Dec/2025
Minerva Neurosciences -4.27M 26.79M Dec/2024
Neurocrine Biosciences USD 787.9M 7M Dec/2025
PTC Therapeutics USD 148.38M 39.31M Dec/2025
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Sarepta Therapeutics USD 43.55M 204.36M Dec/2025
Supernus Pharmaceuticals USD 164.04M 15.23M Dec/2025
UCB EUR 3.19B 621M Dec/2025
Vertex Pharmaceuticals USD 2.72B 62.4M Dec/2025